Paulsen leaves Zimmer
This article was originally published in Clinica
Jeffrey Paulsen has left his post as group president of orthopaedic firm Zimmer's global businesses, effective 20 March. Details of the reasons behind the move, revealed in a filing with the US Securities and Exchange Commission (SEC), were scant, but the company stated: "The separation is not the result of any misconduct." Could it be down to performance? Last month, Zimmer reported flat full-year sales of $4.47 billion, while net profit slipped 1% to $755.0 million (www.clinica.co.uk, 4 February 2013). Mr Paulsen joined the company in January 2010 (www.clinica.co.uk, 14 January 2010); before this, his career covered a range of industries and included a 10-year tenure at one of Zimmer's main rivals, Stryker.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.